Our Pipeline

APEIRON’s portfolio consists of our marketed product Qarziba® (APN311) and a product pipeline of five immune-oncology (IO) product candidates in clinical and discovery stages as well as two product candidates for respiratory treatment.

Our immune-oncology projects include the Cbl-b projects (APN401, APN431), the GD2 programs (APN301) and the novel IO discovery projects (APN411, APN421).

Our respiratory product APN01, a recombinant enzyme of the Renin Angiotensin System is currently tested for treatment of COVID-19, which further validates APEIRON’s robust pipeline.

Indication
Development phase
Disco­very
Phase 1
Phase 2
Phase 3
Market
GD2 Target

APN311 - Qarziba ©

Partnered:

Neuro­blastoma*

Respiratory

APN01 - RhACE2

PAH**

ALI/ARDS**

COVID-19

APN01 - RhACE2

COVID-19

EU/UK/Russia/US
China (preparation)
Other ROA -- Inhalation
Next-Generation Checkpoint Inhibition

APN401 - siRNA-based cell therapy

Various solid tumors***

APN431 - small molecule

Various tumors

Novel IO targets

APN411 - small molecule

Partnered:

Various tumors

APN421 - small molecule

Various tumors

*  EU Market approval, US BLA filing in preparationby EUSA Pharma, Rest of the World filings planned
** Trials sponsored by GSK
*** Phase 1a and 1b completed, Phase 2 planned

rhACE2: recombinant human Angiotensin Converting Enzyme 2
siRNA: small interfering RNA
ROA: route of administration